Non-Metastatic Prostate Cancer Market to Exhibit Growth at a CAGR of 4% During the Forecast Period (2026-2036), as Pharmaceutical Companies Intensify Development of Advanced Therapies | DelveInsight

Summary

Market research report forecasts non-metastatic prostate cancer market to grow at 4% CAGR through 2036, driven by increased disease awareness and advanced therapies including Myovant's Relugolix (ORGOVYX).